BIOMAT Database Logo BIOMAT Database Logo

Development of oseltamivir resistance during oseltamivir therapy in a child with severe 2009 H1N1 influenza. 2010

Daniel Glikman, and Zeev Zonis, and Musa Hindiyeh, and Musa Hindyieh, and Daniela Ram, and Michal Mandelboim, and Ella Mendelson, and Dan Engelhard

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007557 Israel A country in the Middle East, bordering the Mediterranean Sea, between Egypt and Lebanon. The capital is Jerusalem.
D008297 Male Males
D011023 Pneumonia, Staphylococcal Pneumonia caused by infections with bacteria of the genus STAPHYLOCOCCUS, usually with STAPHYLOCOCCUS AUREUS. Staphylococcal Pneumonia,Staphylococcus Aureus Pneumonia,Pneumonia, Staphylococcus Aureus,Pneumonias, Staphylococcal,Pneumonias, Staphylococcus Aureus,Staphylococcal Pneumonias,Staphylococcus Aureus Pneumonias
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Daniel Glikman, and Zeev Zonis, and Musa Hindiyeh, and Musa Hindyieh, and Daniela Ram, and Michal Mandelboim, and Ella Mendelson, and Dan Engelhard
Novel influenza A(H1N1) 2009 in vitro reassortant viruses with oseltamivir resistance.
January 2010, Antiviral therapy,
Daniel Glikman, and Zeev Zonis, and Musa Hindiyeh, and Musa Hindyieh, and Daniela Ram, and Michal Mandelboim, and Ella Mendelson, and Dan Engelhard
Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient.
August 2012, Pediatric transplantation,
Daniel Glikman, and Zeev Zonis, and Musa Hindiyeh, and Musa Hindyieh, and Daniela Ram, and Michal Mandelboim, and Ella Mendelson, and Dan Engelhard
A severely immunocompromised child with uncomplicated oseltamivir-resistant 2009 H1N1 pandemic influenza infection.
August 2012, Pediatric transplantation,
Daniel Glikman, and Zeev Zonis, and Musa Hindiyeh, and Musa Hindyieh, and Daniela Ram, and Michal Mandelboim, and Ella Mendelson, and Dan Engelhard
Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan.
June 2010, Emerging infectious diseases,
Daniel Glikman, and Zeev Zonis, and Musa Hindiyeh, and Musa Hindyieh, and Daniela Ram, and Michal Mandelboim, and Ella Mendelson, and Dan Engelhard
Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.
June 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Daniel Glikman, and Zeev Zonis, and Musa Hindiyeh, and Musa Hindyieh, and Daniela Ram, and Michal Mandelboim, and Ella Mendelson, and Dan Engelhard
Emergence of intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus.
January 2010, Antiviral therapy,
Daniel Glikman, and Zeev Zonis, and Musa Hindiyeh, and Musa Hindyieh, and Daniela Ram, and Michal Mandelboim, and Ella Mendelson, and Dan Engelhard
[Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus].
February 2010, Annales francaises d'anesthesie et de reanimation,
Daniel Glikman, and Zeev Zonis, and Musa Hindiyeh, and Musa Hindyieh, and Daniela Ram, and Michal Mandelboim, and Ella Mendelson, and Dan Engelhard
Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses.
September 2012, The Pediatric infectious disease journal,
Daniel Glikman, and Zeev Zonis, and Musa Hindiyeh, and Musa Hindyieh, and Daniela Ram, and Michal Mandelboim, and Ella Mendelson, and Dan Engelhard
Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009.
October 2009, Releve epidemiologique hebdomadaire,
Daniel Glikman, and Zeev Zonis, and Musa Hindiyeh, and Musa Hindyieh, and Daniela Ram, and Michal Mandelboim, and Ella Mendelson, and Dan Engelhard
Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009.
June 2010, BMC infectious diseases,
Copied contents to your clipboard!